Thoroughbred Financial Services LLC Acquires New Shares in Guardant Health, Inc. $GH

by · The Cerbat Gem

Thoroughbred Financial Services LLC acquired a new stake in Guardant Health, Inc. (NASDAQ:GH – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 6,354 shares of the company’s stock, valued at approximately $648,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GH. V Square Quantitative Management LLC bought a new stake in Guardant Health in the fourth quarter valued at about $27,000. Chesapeake Asset Management LLC bought a new stake in Guardant Health in the fourth quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Guardant Health in the fourth quarter valued at about $31,000. Elyxium Wealth LLC acquired a new position in Guardant Health in the fourth quarter valued at about $35,000. Finally, First Pacific Financial acquired a new position in Guardant Health in the fourth quarter valued at about $43,000. Institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on GH. Guggenheim cut Guardant Health from a “buy” rating to a “buy” rating in a research note on Thursday. Raymond James Financial reissued an “outperform” rating and issued a $129.00 target price on shares of Guardant Health in a research note on Monday, February 23rd. Barclays boosted their target price on Guardant Health from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Citigroup boosted their target price on Guardant Health from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Finally, JPMorgan Chase & Co. boosted their target price on Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Nineteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $129.79.

Read Our Latest Report on Guardant Health

Insider Transactions at Guardant Health

In other news, insider Chris Freeman sold 24,406 shares of the stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $118.67, for a total transaction of $2,896,260.02. Following the transaction, the insider owned 60,034 shares in the company, valued at approximately $7,124,234.78. This trade represents a 28.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John G. Saia sold 10,000 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $125.08, for a total value of $1,250,800.00. Following the transaction, the insider owned 35,950 shares in the company, valued at approximately $4,496,626. This trade represents a 21.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 332,244 shares of company stock valued at $36,156,026. Company insiders own 5.60% of the company’s stock.

Guardant Health Stock Down 2.6%

NASDAQ:GH opened at $129.69 on Friday. The stock’s 50 day moving average price is $95.08 and its two-hundred day moving average price is $99.94. The firm has a market capitalization of $17.20 billion, a price-to-earnings ratio of -38.26 and a beta of 1.48. Guardant Health, Inc. has a 12-month low of $38.03 and a 12-month high of $133.97.

Guardant Health Profile

(Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

Featured Stories

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).